New Year, Fresh Stocks: 3 IPOs That Joined the Market in January

Whether you’re new to the stock market or have been investing for years, initial public offerings (IPOs) can be exciting. An IPO happens when a company begins offering shares of stock for the first time. For investors…

this can be a fantastic opportunity to get in on the ground level, so to speak. If that company ends up becoming the next Amazon, for example, you could potentially make a lot of money over time.

As we continue into the new year, it could be a smart opportunity to invest in fresh stocks. Could any of these three IPOs be a good fit for your portfolio?

1. Amylyx Pharmaceuticals (AMLX)

Amylyx Pharmaceuticals (NASDAQ:AMLX) is a clinical-stage pharmaceutical company focused on creating treatments for neurodegenerative diseases, specifically amyotrophic lateral sclerosis (ALS). It issued its IPO on Jan. 7 at $19 per share, raising $190 million in funding.

Recently, Amylyx submitted an application to the U.S. Food and Drug Administration (FDA) for AMX0035, its drug that aims to treat ALS. The FDA approved the application, setting a target date of June 29 for its regulatory decision. If the FDA eventually approves the drug, it could become a potential new treatment for ALS.

2. Vigil Neuroscience (VIGL)

Vigil Neuroscience (NASDAQ:VIGL) is a biotechnology company that also creates treatments for patients with neurodegenerative diseases. It went public on Jan. 7 with a stock price of $14 per share, raising a total of $98 million after the close of its IPO.

The organization was launched in 2020, and it is the world’s first microglia-focused therapeutics company. It focuses on improving the performance of microglia cells, which are responsible for protecting the brain against neurodegeneration. Through its precision medicine approach, Vigil Neuroscience aims to create treatments that can restore…


Continue reading at THE MOTLEY FOOL


You May Also Like

About the Author: Admin